Document Detail


Adverse and protective influences of adenosine on the newborn and embryo: implications for preterm white matter injury and embryo protection.
MedLine Citation:
PMID:  21228731     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Few signaling molecules have the potential to influence the developing mammal as the nucleoside adenosine. Adenosine levels increase rapidly with tissue hypoxia and inflammation. Adenosine antagonists include the methylxanthines caffeine and theophylline. The receptors that transduce adenosine action are the A1, A2a, A2b, and A3 adenosine receptors (ARs). In the postnatal period, A1AR activation may contribute to white matter injury in the preterm infant by altering oligodendrocyte (OL) development. In models of perinatal brain injury, caffeine is neuroprotective against periventricular white matter injury (PWMI) and hypoxic-ischemic encephalopathy (HIE). Supporting the notion that blockade of adenosine action is of benefit in the premature infant, caffeine reduces the incidence of bronchopulmonary dysplasia and CP in clinical studies. In comparison with the adverse effects on the postnatal brain, adenosine acts via A1ARs to play an essential role in protecting the embryo from hypoxia. Embryo protective effects are blocked by caffeine, and caffeine intake during early pregnancy increases the risk of miscarriage and fetal growth retardation. Adenosine and adenosine antagonists play important modulatory roles during mammalian development. The protective and deleterious effects of adenosine depend on the time of exposure and target sites of action.
Authors:
Scott A Rivkees; Christopher C Wendler
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Pediatric research     Volume:  69     ISSN:  1530-0447     ISO Abbreviation:  Pediatr. Res.     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-03-04     Completed Date:  2011-06-13     Revised Date:  2014-10-26    
Medline Journal Info:
Nlm Unique ID:  0100714     Medline TA:  Pediatr Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  271-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosine / antagonists & inhibitors,  pharmacology*,  therapeutic use
Animals
Caffeine / pharmacology
Embryo, Mammalian / drug effects*,  physiology
Female
Humans
Hypoxia-Ischemia, Brain / drug therapy
Infant, Newborn
Infant, Premature
Leukomalacia, Periventricular / drug therapy
Nerve Fibers, Myelinated / drug effects*,  pathology*
Neuroprotective Agents / pharmacology*,  therapeutic use
Oligodendroglia / drug effects,  pathology
Pregnancy
Protein Isoforms / genetics,  metabolism
Purinergic P1 Receptor Antagonists / pharmacology
Receptors, Purinergic P1 / genetics,  metabolism
Respiration / drug effects
Grant Support
ID/Acronym/Agency:
1R01HD056281/HD/NICHD NIH HHS; 1R01NS068039/NS/NINDS NIH HHS; R01 HD058086/HD/NICHD NIH HHS; R01 HD058086-01A2/HD/NICHD NIH HHS; R01 NS068039/NS/NINDS NIH HHS; R01 NS068039-01A1/NS/NINDS NIH HHS; R21NS051191/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
0/Neuroprotective Agents; 0/Protein Isoforms; 0/Purinergic P1 Receptor Antagonists; 0/Receptors, Purinergic P1; 3G6A5W338E/Caffeine; K72T3FS567/Adenosine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Annual drug update: 2010 in review.
Next Document:  The effect of neutral and acidic oligosaccharides on fecal IL-8 and fecal calprotectin in preterm in...